Jonathan Davies focuses on patent litigation in the life sciences sector with an emphasis on pharmaceutical and biotechnology cases, including Hatch-Waxman litigation and biologics litigation under the Biologics Price Competition and Innovation Act (BPCIA), as well as trade secrets cases.
Jonathan’s litigation experience includes all aspects of pre-trial and trial district court practice, as well as appeals to the US Court of Appeals for the Federal Circuit. He has represented pharmaceutical clients in inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office, and he frequently advises clients in pre-litigation and due diligence investigations.
Before law school, Jonathan completed graduate studies in human physiology and conducted doctoral and post-doctoral research in cellular and molecular biology and genetics. He has served as an adjunct professor at the American University Washington College of Law, where he taught a course on Hatch-Waxman litigation and biosimilars litigation under BPCIA.
Representative experience
- Representing Vifor in patent infringement litigation concerning the iron replacement product Injectafer – Biofer S.p.A. v. Vifor (International) AG
- Representing Scilex and co-plaintiffs in Hatch-Waxman litigation concerning their ZTlido product for the treatment of pain associated with post-herpetic neuralgia against ANDA filers Aveva and Apotex – Scilex Pharmaceuticals, Inc. et al. v. Aveva Drug Delivery Systems, Inc. et al.
- Representing Liquidia in patent litigation and trade secret litigation related to its Yutrepia product for the treatment of pulmonary arterial hypertension - United Therapeutics Corporation v. Liquidia Technologies, Inc.et al.
- Represented Horizon against ANDA filer Apotex in Hatch-Waxman litigation concerning its Pennsaid 2% product (diclofenac sodium) for the treatment of osteoarthritis – Horizon Medicines LLC et al. v. Apotex Inc. et al.
- Represented Liquidia in Hatch-Waxman litigation and parallel IPR proceedings concerning its Yutrepia product for the treatment of pulmonary arterial hypertension – United Therapeutics Corporation v. Liquidia Technologies, Inc.
- Represented Journey Medical in Hatch-Waxman litigation concerning its Zilxi product for the treatment of rosacea, its Amzeeq product for the treatment of acne, and its Qbrexza product for the treatment of primary axillary hyperhidrosis against ANDA filer Perrigo – Journey Medical Corporation et al. v. Perrigo Pharma International DAC
- Represented Journey Medical in Hatch-Waxman litigation concerning its Qbrexza product for the treatment of primary axillary hyperhidrosis against ANDA filer Teva – Journey Medical Corporation et al. v. Teva Pharmaceuticals, Inc. et al.
- Represented defendant CSL Behring in patent litigation concerning its biologic Haegarda for the prophylactic prevention of hereditary angioedema – Shire ViroPharma Inc. v. CSL Behring LLC
- Representing AbbVie in BPCIA litigation related to Humira – AbbVie Inc. et al. v. Boehringer Ingelheim International GmbH et al.
- Represented Forest Labs in Hatch-Waxman litigation for its Saphris product for the treatment of schizophrenia and bipolar disorder against multiple generic drug manufacturers – Forest Laboratories, LLC v. Sigmapharm Laboratories, LLC
- Represented BioDelivery Sciences International in Hatch-Waxman litigation concerning its Belbuca product for pain management – BioDelivery Sciences International, Inc. et al. v. Teva Pharmaceuticals USA, Inc. et al.
- Represented BioDelivery Sciences International in Hatch-Waxman litigation concerning its Bunavail product for maintenance treatment of opioid dependence – BioDelivery Sciences International, Inc. v. Actavis Laboratories UT, Inc. and Actavis, Inc.
- Represented AbbVie in Hatch-Waxman litigation related to its Norvir products for the treatment of HIV against multiple generic drug manufacturers in the US District Court for the Southern District of Ohio and the US District Court for the District of Delaware – AbbVie, Inc. et al. v. Hetero USA, Inc. et al.
- Represented AbbVie in Hatch-Waxman litigation related to its Kaletra products for the treatment of HIV against multiple generic drug manufacturers – AbbVie, Inc. v. Mylan Laboratories, Inc.
- Represented Astellas in Hatch-Waxman litigation related to its immunosuppressant drug Protopic – Astellas US LLC v. Nycomed US Inc.
- Represented Eli Lilly in Hatch-Waxman litigation related to its Cymbalta product against multiple generic drug manufacturers – Eli Lilly and Company v. Wockhardt Ltd.
Awards and recognitions
- Chambers USA, Up and Coming, District of Columbia, IP: Litigation, Chambers and Partners, 2026
- Lawdragon 500 Leading Global IP Lawyers, Lawdragon, 2026
Education
- JD, magna cum laude, The Ohio State University, Moritz College of Law, 2008
- PhD, Molecular Genetics, The Ohio State University, 2004
- MS, Physiology, Pennsylvania State University, 1999
- BS, Biology, Grove City College, 1997
Admissions
- District of Columbia Bar
- Maryland State Bar
Speaking engagements
- Co-presenter, “Clinical Trials and Tribulations: Prosecution and Litigation Implications of Clinical Trial IP and Prior Art,” Consero IP Forum for Life Sciences, December 2024
- Presenter, “The Cost and Worth of a Patent: The Economics of a Paragraph IV Challenge,” ACI Paragraph IV Conference, April 2023
- Presenter, "The Current State of Patent Eligibility Jurisprudence: Redefining What Is Patent-Eligible Subject Matter Post-American Axle v. Neapco," ACI Paragraph IV Conference, November 2021
Publications
- Co-author, “FDA Opens Useful Dialogue on Orange Book Patent Listings,” Law360, June 2020
Membership and activities
- American Intellectual Property Law Association
- Order of the Coif